UCL Cancer Institute Research Trust
UCL Cancer Institute Research Trust
- Funding the Professor of Medical Oncology position at the Royal Free Hospital from 1998-2007
- Providing £1.2million towards the Cancer Clinical Research Facility (initially at the Royal Free but now at the UCL Cancer Institute)
- Obtaining funding from the Copley May Foundation for the Copley May Production Unit at the Royal Free
- Raising £2.5 million towards the construction of, and equipment in, the UCL Cancer Institute ahead of its opening in 2007
- Raising funds for a SPECT/CT scanner, located at University College Hospital but primarily used for research purposes
- Generating support for a number of postgraduate studentships within the Institute
- Purchasing various pieces of highly specialised research equipment within the Institute
Thanks to the generosity of our supporters over the past year, the Cancer Institute Research Trust has raised funds for the following projects:
DepArray Platform (capital cost of equipment £350,000)
The Cancer Institute Research Trust is pleased to announce that it has recently secured funding to purchase a DepArray platform. The DepArray Platform is a vital piece of equipment which allows researchers to carry out ‘liquid biopsies’ in order to study circulating tumour cells (CTCs) in the blood as a means of stratifying cancer therapy. Cancer releases CTCs into the circulation and analysing these cells in blood is similar to carrying out a biopsy but is associated with less risk to the patient. It can also provide ‘real-time’ information about the tumour so that treatment decisions can be based on the cancer as it is now, rather than on archival ‘historical’ tissue. Research is showing us that circulating tumour cells are present in the majority of solid tumours across the entire cancer spectrum. Using the DepArray Platform, our researchers can isolate individual circulating tumour cells and subject them to deep analysis and manipulation. This molecular profiling allows them to extract critical information on both primary and metastatic tumours.
The DepArray Platform is one of the latest and most innovative pieces of cancer research technology available and an essential piece of core equipment. Thanks to the generosity of our supporters, the acquisition of the DepArray Platform means that the UCL Cancer Institute is one of just two cancer research centres in the UK to accommodate this equipment and the sole centre in the South. It will vastly expand the UCL Cancer Institute’s research capabilities and it will also be a major strategic investment for the Institute as it will be made available to and used by other Faculties and Research Institutions.
Bill Lyons Informatics Centre (capital cost of constructing and equipping of facility £2.21 million)
The Cancer Institute Research Trust is pleased to announce that after a two year appeal to raise the necessary funding, the charity has now secured the funding and construction of the new Centre has been completed.
Cancer informatics is the field of science where biology, computer science and highly specialised and powerful information technology merge, resulting in the ability to read and analyse millions of cancer cells and their mutations. The new £2.21 million Bill Lyons Informatics Centre will open in 2014 and will accelerate current cancer research, enable us to pioneer new treatments and ensure we take the next steps in understanding and beating cancer. It will accommodate the specialist skills, necessary computing power and storage for us to carry out this analysis, which will then enable us to create personalised medicine plans for individual patients. This approach will significantly reduce the percentage of patients (from 25-15%) who are non-responsive to their cancer therapy. In addition, we will be able to use these new therapy plans to influence the creation of new cancer drugs, which are often more effective and less invasive than current methods such as chemotherapy. The Informatics Centre will not only serve the large and diverse population of London – it will ultimately support cancer patients across the UK.
Page last modified on 26 mar 14 18:09